{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:13:03Z","timestamp":1783393983735,"version":"3.54.6"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institutes of Health","award":["HHSN272201300020I"],"award-info":[{"award-number":["HHSN272201300020I"]}]},{"DOI":"10.13039\/100008893","name":"University of Iowa","doi-asserted-by":"publisher","award":["HHSN272201300015I"],"award-info":[{"award-number":["HHSN272201300015I"]}],"id":[{"id":"10.13039\/100008893","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007856","name":"Baylor College of Medicine","doi-asserted-by":"publisher","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}],"id":[{"id":"10.13039\/100007856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006939","name":"Emory University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study of a measles-vectored vaccine for chikungunya virus (MV-CHIK) was a Phase 1 randomized, double-blinded, placebo-controlled trial with varying intervals between the 2 doses. The 6 cohorts each had 30 subjects, of which 25 received MV-CHIK and 5 received placebo. The 5 \u00d7 105 TCID50 dose was superior to the 5 \u00d7 104 TCID50 dose, and longer dosing intervals resulted in higher titers in the high dose groups. Mild to moderate injection site and systemic reactogenicity was common but brief. There was no evidence of prolonged vaccine-related arthralgia.<\/jats:p>","DOI":"10.1093\/infdis\/jiaf571","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T12:50:49Z","timestamp":1763211049000},"page":"e641-e645","source":"Crossref","is-referenced-by-count":1,"title":["A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults"],"prefix":"10.1093","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4826-1790","authenticated-orcid":false,"given":"Patricia","family":"Winokur","sequence":"first","affiliation":[{"name":"University of Iowa , Department of Internal Medicine, Iowa City, Iowa ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6985-7964","authenticated-orcid":false,"given":"Theresa E","family":"Hegmann","sequence":"additional","affiliation":[{"name":"University of Iowa , Department of Physician Assistant Studies, Iowa City, Iowa ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0489-0074","authenticated-orcid":false,"given":"Hana M","family":"El Sahly","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-4420","authenticated-orcid":false,"given":"Evan J","family":"Anderson","sequence":"additional","affiliation":[{"name":"Emory University, Department of Medicine and Department of Pediatrics, Atlanta ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DMID 15-0038 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A","family":"Keitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Atmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumi","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inci","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etza","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Rostad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walla","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venus","family":"Shahamatdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Beresney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Tomashek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"2026031710041691300_jiaf571-B1","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2019.1574149","article-title":"51 years in of chikungunya clinical vaccine development: a historical perspective","volume":"15","author":"Reyes-Sandoval","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"2026031710041691300_jiaf571-B2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41572-023-00429-2","article-title":"Chikungunya fever","volume":"9","author":"Bartholomeeusen","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"2026031710041691300_jiaf571-B3","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S1473-3099(16)30385-1","article-title":"Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen","volume":"17","author":"Burt","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2026031710041691300_jiaf571-B4","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/v14050969","article-title":"A review on chikungunya virus epidemiology, pathogenesis and current vaccine development","volume":"14","author":"de Lima Cavalcanti","year":"2022","journal-title":"Viruses"},{"key":"2026031710041691300_jiaf571-B5","doi-asserted-by":"crossref","first-page":"1413250","DOI":"10.3389\/fmicb.2024.1413250","article-title":"Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions","volume":"15","author":"Shaikh","year":"2024","journal-title":"Front Microbiol"},{"key":"2026031710041691300_jiaf571-B6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2026031710041691300_jiaf571-B7","doi-asserted-by":"crossref","first-page":"S500","DOI":"10.1093\/infdis\/jiw369","article-title":"Chikungunya virus vaccines: viral vector-based approaches","volume":"214","author":"Ramsauer","year":"2016","journal-title":"J Infect Dis"},{"key":"2026031710041691300_jiaf571-B8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14760584.2019.1562908","article-title":"Measles-vectored vaccine approaches against viral infections: a focus on chikungunya","volume":"18","author":"Gerke","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"2026031710041691300_jiaf571-B9","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2019","journal-title":"Lancet"},{"key":"2026031710041691300_jiaf571-B10","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"},{"key":"2026031710041691300_jiaf571-B11","doi-asserted-by":"crossref","first-page":"612747","DOI":"10.3389\/fimmu.2021.612747","article-title":"Optimize prime\/boost vaccine strategies: trained immunity as a new player in the game","volume":"12","author":"Palgen","year":"2021","journal-title":"Front Immunol"},{"key":"2026031710041691300_jiaf571-B12","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/cid\/ciae173","article-title":"A phase 2 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of different prime-boost vaccination schedules of 2013 and 2017 A(H7N9) inactivated influenza virus vaccines administered with and without AS03 adjuvant in healthy US adults","volume":"78","author":"Rostad","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026031710041691300_jiaf571-B13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2024.01.033","article-title":"Live-attenuated chikungunya virus vaccine","volume":"187","author":"Ng","year":"2024","journal-title":"Cell"},{"key":"2026031710041691300_jiaf571-B14","doi-asserted-by":"crossref","first-page":"2301573","DOI":"10.1080\/21505594.2023.2301573","article-title":"Ixchiq (VLA1553): the first FDA-approved vaccine to prevent disease caused by chikungunya virus infection","volume":"15","author":"Ly","year":"2024","journal-title":"Virulence"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf571\/65630720\/jiaf571.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/3\/e641\/65630720\/jiaf571.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/3\/e641\/65630720\/jiaf571.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:04:23Z","timestamp":1773756263000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/3\/e641\/8354605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,28]]},"published-print":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf571","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,15]]},"published":{"date-parts":[[2025,11,28]]}}}